NATERA INC
NTRANASDAQTrading Snapshot
- Day Range
- $408.55 β $414.78
- 52-Week Range
- $157.43 β $421.64
- Volume
- $3.19B
- Avg Volume
- $2.28B
- Shares Outstanding
- 143.2M
- Next Earnings
- Nov 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.31B
- Last Q Revenue
- $753M
- P/E Ratio
- -302.3
- P/S Ratio
- 21.8x
- EPS (TTM)
- $-1.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.6%
Why Investors Own NTRA
- βHigh-growth profile β revenue up +0.1% YoY with expanding US Equity exposure.
- βHealthy economics β 30% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NATERA INC
NTRAAbout NATERA INC
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates

Natera, UnitedHealth Group And A Tech Stock On CNBC's βFinal Trades'
On CNBC's βHalftime Report Final Trades,β Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE:HPE).

Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.

Natera (NASDAQ:NTRA) Hits New 12-Month High β Hereβs Why
Natera, Inc. (NASDAQ: NTRA - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday. The stock traded as high as $371.59 and last traded at $366.2210, with a volume of 2446 shares changing hands.

3 Analysts, 3 Trades to Make Today
Louis says buy the AI dip

Uber, Micron, Datadog And A Health Care Stock: CNBC's βFinal Trades'
On CNBC's βHalftime Report Final Trades,β Bryn Talkington, managing partner of Requisite Capital Management, picked Uber Technologies, Inc. (NYSE:UBER).

Signateraβ’ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals